doi.org/10.51891/rease.v10i9.15680

UNRAVELING THE GENETIC AND BIOLOGICAL INTRICACIES OF ANESTHESIA FOR CHRONIC PAIN: A COMPREHENSIVE REVIEW OF COMT GENE VARIATIONS AND THEIR IMPACT ON TREATMENT EFFICACY ACROSS ETHNICITIES

Rafael Augusto Jesus Arruda[1]
Vinícius Côgo Destefani[2]
Afrânio Côgo Destefani[3]

ABSTRACT: Chronic pain management remains a significant challenge, with individual responses to anesthesia and analgesics varying widely due to genetic and biological factors. This review explores the influence of the catechol-O-methyltransferase (COMT) gene, particularly the Val158Met polymorphism, on pain sensitivity and opioid efficacy across different ethnicities. COMT variations play a crucial role in modulating pain perception and analgesic response, with Met allele carriers generally exhibiting higher pain sensitivity and lower opioid requirements. Ethnic differences in COMT gene frequencies further impact anesthesia efficacy, underscoring the importance of personalized pain management strategies. The review also discusses the potential of pharmacogenetic approaches, a beacon of hope for improving treatment outcomes. It highlights emerging technologies in genetic-based pain management, such as epigenetic modulation and gene editing.

Keywords: COMT gene. Val158Met polymorphism. Chronic pain management. Pharmacogenetics. Personalized anesthesia.

INTRODUCTION

Chronic pain represents a significant global health burden, affecting millions of individuals worldwide and presenting a complex challenge for healthcare providers. The management of chronic pain often involves the use of anesthesia and analgesics, particularly opioids, to alleviate suffering and improve quality of life. However, the efficacy of these treatments can vary significantly among patients, leading researchers to investigate the underlying genetic and biological factors that influence individual responses to pain management strategies (Packiasabapathy et al., 2018).

[1]Centro Universitário Metropolitano da Amazônia – UNIFAMAZ.
[2]Molecular Dynamics and Modeling Laboratory (DynMolLab).
[3]Santa Casa de Misericórdia de Vitoria Higher School of Sciences - EMESCAM.

Recent advances in genomics and pharmacogenomics have shed light on the role of genetic variations in modulating pain perception and analgesic responses. Of particular interest is the catechol-O-methyltransferase (COMT) gene, which plays a crucial role in the metabolism of catecholamines and has been implicated in pain sensitivity and opioid efficacy (Tammimäki & Männistö, 2012). The Val158Met polymorphism (rs4680) of the COMT gene has emerged as a key genetic factor influencing pain perception and analgesic requirements in chronic pain management (Rakvåg et al., 2005).

This review, a significant contribution to chronic pain management, aims to comprehensively analyze the genetic and biological insights related to anesthesia for chronic pain. By focusing on the COMT gene Val158Met polymorphism and its impact on treatment efficacy across different ethnicities, we delve into the molecular mechanisms that underlie the influence of COMT variations on pain sensitivity and opioid response. This research is informative and crucial for understanding the variations in treatment outcomes among various ethnic groups and discussing the implications for personalized pain management strategies.

By synthesizing the current knowledge in this field, we aim to contribute to a better understanding of the complex interplay between genetics, ethnicity, and anesthesia efficacy in chronic pain management. This review will provide valuable insights for clinicians and researchers working to optimize pain treatment protocols and develop more targeted, patient-specific approaches to chronic pain management.

METHODOLOGY

This narrative review employed a comprehensive literature search strategy to identify relevant studies and review articles related to genetic and biological insights in anesthesia for chronic pain. The focus was on the COMT gene Val158Met polymorphism and its impact across different ethnicities. We systematically searched the following databases: PubMed, Scopus, Web of Science, ScienceDirect, and JSTOR, ensuring a thorough review process.

Search terms included combinations and variations of the following keywords: "chronic pain," "anesthesia," "COMT gene," "Val158Met polymorphism," "opioid response,"

"ethnicity," "pharmacogenetics," "pain sensitivity," and "personalized medicine." The search was limited to articles published in English between 2000 and 2024 to ensure the most recent and relevant research was included.

The inclusion criteria for selected studies were

1. Original research articles, systematic reviews, or meta-analyses.
2. Studies focusing on the role of COMT gene variations in chronic pain management.
3. Research investigating the impact of ethnicity on anesthesia efficacy and opioid response.
4. Studies examining the pharmacogenetics of pain management.
5. Clinical trials evaluating the efficacy of anesthesia and analgesics about genetic factors.

Exclusion criteria included

1. Case reports and small case series.
2. Studies focusing solely on acute pain.
3. Articles not peer-reviewed or published in predatory journals.

The selected articles were critically appraised for their methodological quality, sample size, and relevance to the review's objectives. Data extraction focused on key findings related to COMT gene variations, their impact on pain sensitivity and opioid response, ethnic differences in treatment outcomes, and implications for personalized pain management.

The synthesized information was organized into thematic sections to provide a comprehensive overview of the current state of knowledge in the field. Throughout the review, we maintained a balanced approach, presenting a fair assessment of the evidence and highlighting consistent findings and areas of controversy or uncertainty.

RESULTS

1. COMT Gene Variations and Their Impact on Pain Sensitivity

The catechol-O-methyltransferase (COMT) gene, located on chromosome 22q11.2, encodes an enzyme responsible for the degradation of catecholamines, including dopamine and norepinephrine. The Val158Met polymorphism (rs4680) of the COMT gene has been extensively studied for its role in pain perception and analgesic response. This single nucleotide polymorphism results in a valine (Val) to methionine (Met) substitution at codon 158, leading to altered enzyme activity (Tammimäki & Männistö, 2012).

Research has consistently shown that individuals carrying the Met allele exhibit reduced COMT enzyme activity, resulting in higher levels of catecholamines in the central nervous system. This alteration in neurotransmitter levels has been associated with increased pain sensitivity and a more pronounced response to painful stimuli (Kambur & Männistö, 2010). In a meta-analysis conducted by Tammimäki and Männistö (2012), the authors found a significant association between the Met allele and increased pain sensitivity across various chronic pain conditions, including fibromyalgia, temporomandibular joint disorder, and chronic widespread pain.

Animal and human studies have elucidated the molecular mechanisms underlying this increased pain sensitivity in Met allele carriers. Zubieta et al. (2003) demonstrated that individuals homozygous for the Met allele (Met/Met genotype) showed increased μ-opioid receptor binding potential in several brain regions associated with pain processing, including the thalamus, nucleus accumbens, and amygdala. This increased binding potential suggests a compensatory upregulation of opioid receptors in response to higher endogenous opioid tone, which may contribute to altered pain perception and analgesic response.

Furthermore, the impact of COMT variations on pain sensitivity extends beyond acute experimental pain to chronic pain conditions. Diatchenko et al. (2006) found that the COMT gene haplotype, including the Val158Met polymorphism, strongly predicted temporomandibular joint disorder onset and chronicity. Their study revealed that individuals with the low COMT activity haplotype (including the Met allele) were likelier to develop persistent pain and exhibit lower pain thresholds.

These findings highlight the critical role of COMT gene variations in modulating pain sensitivity and underscore the potential for using genetic information to predict individual susceptibility to chronic pain conditions. Understanding these genetic influences can provide valuable insights for developing targeted prevention strategies and personalized pain management approaches.

2. COMT Gene Variations and Opioid Response in Chronic Pain Management

The influence of COMT gene variations on opioid response has been a subject of intense research, given the widespread use of opioids in chronic pain management. Several studies have demonstrated that the Val158Met polymorphism significantly impacts opioid efficacy and dosage requirements in various clinical settings.

Rakvåg et al. (2005) conducted a landmark study investigating the relationship between COMT genotypes and morphine requirements in cancer patients with pain. Their findings revealed that patients homozygous for the Met allele (Met/Met genotype) required significantly lower doses of morphine to achieve adequate pain relief compared to those with the Val/Val genotype. This observation suggests that individuals with reduced COMT enzyme activity may be more sensitive to the analgesic effects of opioids, potentially due to altered endogenous opioid tone and μ-opioid receptor function.

Expanding on these findings, a subsequent study by Rakvåg et al. (2008) explored the interaction between COMT genotypes and other genetic factors in determining opioid requirements. They found that the combination of COMT Val158Met and μ-opioid receptor (OPRM1) A118G polymorphisms had a more pronounced effect on morphine dosage than either polymorphism alone. This highlights the complex interplay between multiple genetic factors in shaping individual responses to opioid therapy.

The impact of COMT variations on opioid response extends beyond cancer-related pain to other chronic pain conditions. Cargnin et al. (2013) investigated the influence of the Val158Met polymorphism on the clinical response to intrathecal morphine in patients with chronic low back pain. Their results showed that Met allele carriers experienced more pain relief and required lower morphine doses than Val/Val homozygotes. Interestingly, they also

observed an opposite effect for the response to triptans in migraine patients, suggesting that the influence of COMT variations may be drug-specific and depend on the underlying pain mechanism.

The role of COMT in opioid response is not limited to adults; pediatric studies have also demonstrated its significance. Wang et al. (2024) investigated the influence of COMT gene polymorphisms on sufentanil analgesic effect in children with fractures. They found that children carrying the Met allele required lower doses of sufentanil for postoperative pain management and experienced better analgesic effects than those with the Val/Val genotype.

These findings have important implications for personalized pain management strategies. Patients with the Met/Met genotype may benefit from lower initial opioid doses to achieve adequate pain relief while minimizing the risk of adverse effects. Conversely, individuals with the Val/Val genotype may require higher opioid doses to achieve the same level of analgesia, potentially putting them at increased risk for opioid-related side effects and the development of tolerance.

However, it is essential to note that the relationship between COMT genotype and opioid response is not always straightforward. Some studies have reported conflicting results or failed to find significant associations. For example, Klepstad et al. (2011) found no significant effect of the Val158Met polymorphism on opioid doses in a large cohort of cancer pain patients. These discrepancies highlight the need for further research to elucidate the complex interactions between genetic factors and clinical variables in determining opioid response.

3. Ethnic Variations in COMT Gene Frequency and Their Impact on Anesthesia Efficacy

The frequency of COMT gene variants, particularly the Val158Met polymorphism, varies significantly across ethnic populations. These variations in allele frequencies can have essential implications for anesthesia efficacy and pain management strategies in diverse patient populations.

Studies have consistently shown that the frequency of the Met allele is higher in Asian populations than in European and African populations. For instance, Palmatier et al. (1999)

reported Met allele frequencies of approximately 0.27 in European populations, 0.52 in Asian populations, and 0.32 in African populations. These ethnic differences in allele frequencies can contribute to variations in pain sensitivity and analgesic response across different populations.

The impact of these ethnic variations in COMT gene frequency on anesthesia efficacy has been investigated in several studies. Tan et al. (2008) examined ethnic differences in pain perception and patient-controlled analgesia (PCA) usage for postoperative pain in a multiethnic Asian population. They found that Indian patients reported higher pain scores and required more morphine compared to Chinese and Malay patients, even after controlling for factors such as age and body mass index. While this study did not directly genotype patients for COMT variations, the observed ethnic differences in pain response suggest a potential role for genetic factors, including COMT polymorphisms.

Somogyi et al. (2016) conducted a more comprehensive study investigating the ethnicity-dependent influence of innate immune genetic markers, including COMT, on morphine PCA requirements and adverse effects in postoperative pain. They observed that the association between COMT genotypes and postoperative pain outcomes varied among ethnic groups. Specifically, they found that Chinese patients with the variant COMT rs4680 genotypes experienced a higher incidence of postoperative pain, while this association was not observed in Malay or Indian cohorts. This study highlights the complex interplay between genetic factors and ethnicity in determining pain responses and analgesic requirements.

The variations in COMT gene frequency across ethnicities can also influence the occurrence of side effects associated with anesthesia and opioid therapy. Khan et al. (2023) investigated the role of the COMT rs4680 SNP in patients' response to tramadol and its adverse effects in the Pakistani population. They found that patients with the Met/Met genotype experienced more adverse effects, such as nausea and sedation, compared to those with the Val/Val genotype. This finding is consistent with the higher sensitivity to opioids observed in Met allele carriers. It underscores the importance of genetic factors in predicting and managing treatment-related side effects.

These ethnic variations in COMT gene frequency and their impact on anesthesia efficacy have important implications for clinical practice. Healthcare providers should be aware of the potential differences in pain sensitivity and analgesic requirements among different ethnic groups and consider these factors when developing pain management strategies. Additionally, the development of population-specific genetic screening tools and dosing guidelines may be necessary to optimize pain management across diverse patient populations.

4. Pharmacogenetic Approaches to Personalized Pain Management

The growing understanding of genetic influences on pain perception and analgesic response has paved the way for pharmacogenetic approaches to personalized pain management. These approaches aim to tailor analgesic therapies based on an individual's genetic profile, potentially improving treatment efficacy and reducing adverse effects.

Several studies have demonstrated the potential benefits of pharmacogenetic-guided pain management strategies. Smith et al. (2019) conducted a pragmatic clinical trial investigating the impact of CYP2D6-guided opioid therapy on pain control in patients with chronic pain. While this study focused on CYP2D6 rather than COMT, it provided compelling evidence for the value of genetic testing in optimizing pain management. The authors found that patients receiving genotype-guided therapy experienced significantly improved pain control compared to those receiving standard care.

Building on this concept, Agulló et al. (2023) conducted a randomized, double-blind, controlled study to evaluate the efficacy of pharmacogenetic-guided opioid therapy in improving chronic pain outcomes and comorbid mental health. Their study included genetic testing for several pain-related genes, including COMT. The results showed that patients receiving pharmacogenetic-guided therapy experienced significant improvements in pain intensity, quality of life, and mental health outcomes compared to those receiving standard care. This study provides strong evidence for the potential of personalized pain management strategies based on genetic profiling.

Implementing pharmacogenetic approaches in clinical practice requires careful consideration of several factors. Owusu Obeng et al. (2017) provided a comprehensive review of opioid pharmacogenetics and considerations for pain management. They emphasized the importance of considering multiple genetic factors, including COMT, OPRM1, and CYP2D6, in developing personalized pain management strategies. The authors also highlighted the need for clinical decision support tools to help healthcare providers interpret genetic test results and make informed treatment decisions.

One promising approach to personalized pain management is the development of genetic risk scores that incorporate multiple genetic variants. Packiasabapathy et al. (2018) proposed a comprehensive genetic risk score for perioperative pain management, including COMT and other pain-related genes. This approach may provide a more accurate prediction of individual pain sensitivity and analgesic requirements than single-gene testing.

However, implementing pharmacogenetic approaches in routine clinical practice faces several challenges. These include the need for robust clinical evidence supporting genetic testing, the development of standardized testing protocols and interpretation guidelines, and addressing issues related to cost-effectiveness and accessibility. Additionally, the complex interactions between genetic and environmental factors in pain perception and analgesic response necessitate ongoing research to refine and validate personalized pain management strategies.

5. Future Directions and Emerging Technologies in Genetic-Based Pain Management

As our understanding of the genetic basis of pain perception and analgesic response continues to evolve, several promising avenues for future research and technological developments are emerging in genetic-based pain management.

One area of active research is the exploration of epigenetic mechanisms in chronic pain and their potential as therapeutic targets. Moreno et al. (2021) demonstrated the potential of targeted in situ repression of the NaV1.7 sodium channel gene (SCN9A) for long-lasting analgesia in mice. This approach, which involves epigenetic modification of pain-related

genes, could potentially be applied to COMT and other genes involved in pain perception and opioid response. Further research in this area may lead to the development of novel, gene-specific therapies for chronic pain management.

Another promising direction is integrating genetic information with other biomarkers and clinical data to create more comprehensive predictive models for pain management. Machine learning and artificial intelligence approaches could be employed to analyze complex datasets incorporating genetic, epigenetic, proteomic, and clinical variables to develop more accurate and personalized pain management strategies (Fernández Robles et al., 2012).

Advancements in gene editing technologies, such as CRISPR-Cas9, may also open up new possibilities for treating chronic pain conditions with a genetic basis. While ethical considerations and safety concerns must be carefully addressed, gene editing approaches could correct or modulate pain-related genetic variations in select cases of severe, treatment-resistant chronic pain (Dib-Hajj & Waxman, 2019).

The development of rapid, point-of-care genetic testing technologies could facilitate the widespread implementation of pharmacogenetic approaches in clinical practice. Such technologies would allow for real-time genetic profiling and immediate tailoring of pain management strategies based on individual genetic variations (Lucenteforte et al., 2019).

Finally, exploring gene-environment interactions and the role of the microbiome in pain perception and analgesic response represent emerging areas of research that may provide additional insights into personalized pain management strategies. Studies investigating how environmental factors and the gut microbiome interact with genetic variations to influence pain sensitivity and opioid efficacy could lead to more holistic approaches to chronic pain management (van Reij et al., 2019).

DISCUSSION

The comprehensive review of genetic and biological insights related to anesthesia for chronic pain, with a particular focus on the COMT gene Val158Met polymorphism, reveals the complex interplay between genetic factors, ethnicity, and treatment outcomes in pain

management. The findings presented in this review have significant implications for clinical practice and future research directions in personalized pain medicine.

One of the most striking observations is the consistent association between the COMT Val158Met polymorphism and pain sensitivity across various chronic pain conditions. The higher pain sensitivity observed in Met allele carriers provides a biological basis for the variability in individuals' pain experiences. It underscores the importance of genetic factors in pain assessment and management strategies. This knowledge could be precious in identifying individuals at higher risk of developing chronic pain conditions, allowing for early intervention and prevention strategies.

The impact of COMT variations on opioid response presents both opportunities and challenges for pain management. The observation that Met allele carriers generally require lower opioid doses for effective pain relief suggests the potential for more targeted and efficient pain management strategies. By tailoring initial opioid doses based on COMT genotype, clinicians may be able to achieve better pain control while minimizing the risk of adverse effects and opioid dependence. However, the conflicting results reported in some studies highlight the need for further research to elucidate the complex interactions between genetic factors and clinical variables in determining opioid response.

The ethnic variations in COMT gene frequency and their impact on anesthesia efficacy underscore the importance of considering population genetics in pain management strategies. The higher frequency of the Met allele in Asian populations compared to European and African populations may contribute to observed differences in pain sensitivity and analgesic requirements among these groups. This knowledge is crucial for developing population-specific guidelines for pain management and highlights the need for more diverse representation in pain research studies.

The emerging field of pharmacogenetic-guided pain management shows great promise for improving treatment outcomes in chronic pain patients. The positive results from studies implementing genotype-guided therapy provide strong evidence for the potential benefits of personalized pain management strategies. However, successfully

implementing these approaches in routine clinical practice will require addressing several challenges, including developing standardized testing protocols, interpretation guidelines, and clinical decision support tools.

The future directions and emerging technologies discussed in this review offer exciting possibilities for advancing the field of genetic-based pain management. The potential applications of epigenetic modulation, gene editing technologies, and rapid point-of-care genetic testing could revolutionize chronic pain treatment. However, these advancements also raise important ethical considerations that must be carefully addressed as the field progresses.

Several limitations and areas for future research should be noted. First, while the COMT Val158Met polymorphism has been extensively studied, other genetic variations likely play essential roles in pain perception and analgesic response. Future studies should aim to develop more comprehensive genetic profiles that incorporate multiple pain-related genes to improve the accuracy of personalized pain management strategies.

Second, the majority of studies reviewed focused on opioid medications, particularly morphine. Given the ongoing opioid crisis and the need for alternative pain management strategies, future research should explore the impact of genetic variations on the efficacy of non-opioid analgesics and non-pharmacological pain management approaches.

Third, the long-term outcomes of pharmacogenetic-guided pain management strategies must be evaluated through large-scale, longitudinal studies. These studies should assess not only pain control but also quality of life, functional outcomes, and the potential for reducing opioid dependence and abuse.

Finally, integrating genetic information with other clinical and biological data, including neuroimaging, proteomics, and microbiome analysis, may provide a more comprehensive understanding of individual pain experiences and treatment responses. The development of interdisciplinary research initiatives and advanced data analysis techniques will be crucial for realizing the full potential of personalized pain medicine.

CONCLUSION

This comprehensive review of genetic and biological insights related to anesthesia for chronic pain, focusing on the COMT gene Val158Met polymorphism, highlights the significant progress made in understanding the genetic basis of pain perception and analgesic response. The consistent association between COMT variations and pain sensitivity, along with their impact on opioid efficacy, provides a strong foundation for the development of personalized pain management strategies.

Ethnic variations in COMT gene frequency and their influence on anesthesia efficacy underscore the importance of considering population genetics in pain research and clinical practice. These findings emphasize the need for more diverse and representative studies to develop population-specific guidelines for pain management.

The emerging field of pharmacogenetic-guided pain management shows great promise for improving treatment outcomes in chronic pain patients. However, successfully implementing these approaches in routine clinical practice will require addressing several challenges, including developing standardized testing protocols, interpretation guidelines, and clinical decision-support tools.

Future research directions, including the exploration of epigenetic mechanisms, gene-environment interactions, and the integration of genetic information with other biomarkers, offer exciting possibilities for advancing the field of personalized pain medicine. As these areas continue to develop, addressing ethical considerations and ensuring equitable access to genetic-based pain management strategies will be crucial.

In conclusion, the insights gained from genetic and biological research in chronic pain management can potentially revolutionize the field of anesthesia and pain medicine. By incorporating genetic information into clinical decision-making, healthcare providers may be able to offer more targeted, effective, and safer pain management strategies for individuals suffering from chronic pain. As we unravel the complex interplay between genetics, biology, and pain, the goal of genuinely personalized pain medicine comes ever closer to reality.

REFERENCES

AGULLÓ, L., Aguado, I., Muriel, J., et al. (2023). Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study. International Journal of Molecular Sciences, 24(13), 10754. https://doi.org/10.3390/ijms241310754

CARGNIN, S., Magnani, F., Viana, M., et al. (2013). An Opposite-Direction Modulation of the COMT Val158Met Polymorphism on the Clinical Response to Intrathecal Morphine and Triptans. The Journal of Pain, 14(10), 1097-106. https://doi.org/10.1016/j.jpain.2013.04.006

DE Gregori, M., Garbin, G., De Gregori, S., et al. (2013). Genetic Variability at COMT but Not at OPRM1 and UGT2B7 Loci Modulates Morphine Analgesic Response in Acute Postoperative Pain. European Journal of Clinical Pharmacology, 69(9), 1651-8. https://doi.org/10.1007/s00228-013-1523-7

DIATCHENKO, L., Nackley, A. G., Slade, G. D., et al. (2006). Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain, 125(3), 216-224. https://doi.org/10.1016/j.pain.2006.05.024

DIB-Hajj, S. D., & Waxman, S. G. (2019). Sodium Channels in Human Pain Disorders: Genetics and Pharmacogenomics. Annual Review of Neuroscience, 42, 87-106. https://doi.org/10.1146/annurev-neuro-070918-050144

FERNÁNDEZ Robles, C. R., Degnan, M., & Candiotti, K. A. (2012). Pain and Genetics. Current Opinion in Anaesthesiology, 25(4), 444-9. https://doi.org/10.1097/ACO.0b013e3283556228

KAMBUR, O., & Männistö, P. T. (2010). Catechol-O-Methyltransferase and Pain. International Review of Neurobiology, 95, 227-79. https://doi.org/10.1016/B978-0-12-381326-8.00010-7

Khan, A., Waheed, A., Afsar, T., et al. (2023). Unraveling Catechol-O-Methyltransferase Rs4680 SNP's Role in Patients' Response to Tramadol and Its Adverse Effects: A Pharmacogenetics Insight Into Postoperative Pain Management. Journal of Clinical Medicine, 13(1), 249. https://doi.org/10.3390/jcm13010249

KLEPSTAD, P., Fladvad, T., Skorpen, F., et al. (2011). Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain, 152(5), 1139-1145. https://doi.org/10.1016/j.pain.2011.01.040

LUCENTEFORTE, E., Vannacci, A., Crescioli, G., et al. (2019). Opioid Response in Paediatric Cancer Patients and the Val158Met Polymorphism of the Human Catechol-O-

Methyltransferase (COMT) Gene: An Italian Study on 87 Cancer Children and a Systematic Review. BMC Cancer, 19(1), 113. https://doi.org/10.1186/s12885-019-5310-4

MORENO, A. M., Alemán, F., Catroli, G. F., et al. (2021). Long-Lasting Analgesia via Targeted in Situ Repression of NaV1.7 in Mice. Science Translational Medicine, 13(584), eaay9056. https://doi.org/10.1126/scitranslmed.aay9056

OWUSU Obeng, A., Hamadeh, I., & Smith, M. (2017). Review of Opioid Pharmacogenetics and Considerations for Pain Management. Pharmacotherapy, 37(9), 1105-1121. https://doi.org/10.1002/phar.1986

PACKIASABAPATHY, S., Horn, N., & Sadhasivam, S. (2018). Genetics of Perioperative Pain Management. Current Opinion in Anaesthesiology, 31(6), 749-755. https://doi.org/10.1097/ACO.0000000000000660

PALMATIER, M. A., Kang, A. M., & Kidd, K. K. (1999). Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biological Psychiatry, 46(4), 557-567. https://doi.org/10.1016/s0006-3223(99)00098-0

RAKVÅG, T. T., Klepstad, P., Baar, C., et al. (2005). The Val158Met Polymorphism of the Human Catechol-O-Methyltransferase (COMT) Gene May Influence Morphine Requirements in Cancer Pain Patients. Pain, 116(1-2), 73-8. https://doi.org/10.1016/j.pain.2005.03.032

RAKVÅG, T. T., Ross, J. R., Sato, H., et al. (2008). Genetic Variation in the Catechol-O-Methyltransferase (COMT) Gene and Morphine Requirements in Cancer Patients With Pain. Molecular Pain, 4, 64. https://doi.org/10.1186/1744-8069-4-64

SMITH, D. M., Weitzel, K. W., Elsey, A. R., et al. (2019). CYP2D6-guided Opioid Therapy Improves Pain Control in CYP2D6 Intermediate and Poor Metabolizers: A Pragmatic Clinical Trial. Genetics in Medicine, 21(8), 1842-1850. https://doi.org/10.1038/s41436-018-0431-8

SOMOGYI, A. A., Sia, A. T., Tan, E. C., et al. (2016). Ethnicity-Dependent Influence of Innate Immune Genetic Markers on Morphine PCA Requirements and Adverse Effects in Postoperative Pain. Pain, 157(11), 2458-2466. https://doi.org/10.1097/j.pain.0000000000000661

TAMMIMÄKI, A., & Männistö, P. T. (2012). Catechol-O-Methyltransferase Gene Polymorphism and Chronic Human Pain: a Systematic Review and Meta-Analysis. Pharmacogenetics and Genomics, 22(9), 673-91. https://doi.org/10.1097/FPC.0b013e3283560c46

TAN, E. C., Lim, Y., Teo, Y. Y., et al. (2008). Ethnic Differences in Pain Perception and Patient-Controlled Analgesia Usage for Postoperative Pain. The Journal of Pain, 9(9), 849-55. https://doi.org/10.1016/j.jpain.2008.04.004

VAN Reij, R. R. I., Joosten, E. A. J., & van den Hoogen, N. J. (2019). Dopaminergic Neurotransmission and Genetic Variation in Chronification of Post-Surgical Pain. British Journal of Anaesthesia, 123(6), 853-864. https://doi.org/10.1016/j.bja.2019.07.028

WANG, H., An, J., Zhong, S., et al. (2024). The Influence of COMT and ABCB1 Gene Polymorphisms on Sufentanil Analgesic Effect for Postoperative Pain in Children With Fracture. Medicine, 103(17), e37980. https://doi.org/10.1097/MD.0000000000037980

ZUBIETA, J. K., Heitzeg, M. M., Smith, Y. R., et al. (2003). COMT val158met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science, 299(5610), 1240-1243. https://doi.org/10.1126/science.1078546